NO20085000L - Salter og krystallmodifikasjoner derav - Google Patents

Salter og krystallmodifikasjoner derav

Info

Publication number
NO20085000L
NO20085000L NO20085000A NO20085000A NO20085000L NO 20085000 L NO20085000 L NO 20085000L NO 20085000 A NO20085000 A NO 20085000A NO 20085000 A NO20085000 A NO 20085000A NO 20085000 L NO20085000 L NO 20085000L
Authority
NO
Norway
Prior art keywords
salts
crystal modifications
phenyl
crystalline forms
crystal
Prior art date
Application number
NO20085000A
Other languages
English (en)
Norwegian (no)
Inventor
Xinglong Jiang
Lili Feng
Piotr Karpinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20085000L publication Critical patent/NO20085000L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20085000A 2006-05-23 2008-11-28 Salter og krystallmodifikasjoner derav NO20085000L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80283606P 2006-05-23 2006-05-23
PCT/US2007/069327 WO2007140154A2 (en) 2006-05-23 2007-05-21 Salts and crystal modifications thereof

Publications (1)

Publication Number Publication Date
NO20085000L true NO20085000L (no) 2008-12-23

Family

ID=38704747

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085000A NO20085000L (no) 2006-05-23 2008-11-28 Salter og krystallmodifikasjoner derav

Country Status (28)

Country Link
US (1) US7977330B2 (ru)
EP (1) EP2029556B1 (ru)
JP (2) JP2009538330A (ru)
KR (1) KR20090009898A (ru)
CN (1) CN101448796B (ru)
AR (1) AR061056A1 (ru)
AT (1) ATE486858T1 (ru)
AU (1) AU2007267671A1 (ru)
BR (1) BRPI0712556A2 (ru)
CA (1) CA2650514A1 (ru)
CL (1) CL2007001454A1 (ru)
CR (1) CR10431A (ru)
DE (1) DE602007010286D1 (ru)
EC (1) ECSP088900A (ru)
ES (1) ES2355166T3 (ru)
GT (1) GT200800253A (ru)
IL (1) IL195008A0 (ru)
MA (1) MA30482B1 (ru)
MX (1) MX2008014836A (ru)
NO (1) NO20085000L (ru)
PE (1) PE20080261A1 (ru)
PL (1) PL2029556T3 (ru)
PT (1) PT2029556E (ru)
RU (1) RU2008150627A (ru)
TN (1) TNSN08477A1 (ru)
TW (1) TW200815375A (ru)
WO (1) WO2007140154A2 (ru)
ZA (1) ZA200809096B (ru)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL375860A1 (en) * 2002-09-20 2005-12-12 Arrow Therapeutics Limited Benzodiazepine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
MX2008014836A (es) 2008-12-01
TW200815375A (en) 2008-04-01
ZA200809096B (en) 2009-11-25
GT200800253A (es) 2009-04-29
KR20090009898A (ko) 2009-01-23
PL2029556T3 (pl) 2011-04-29
CR10431A (es) 2009-01-07
US7977330B2 (en) 2011-07-12
WO2007140154A3 (en) 2008-03-20
AR061056A1 (es) 2008-07-30
ES2355166T3 (es) 2011-03-23
DE602007010286D1 (de) 2010-12-16
TNSN08477A1 (en) 2010-04-14
RU2008150627A (ru) 2010-06-27
CA2650514A1 (en) 2007-12-06
JP2013075910A (ja) 2013-04-25
CN101448796A (zh) 2009-06-03
PE20080261A1 (es) 2008-04-18
CN101448796B (zh) 2012-09-26
IL195008A0 (en) 2009-08-03
ECSP088900A (es) 2008-12-30
AU2007267671A1 (en) 2007-12-06
BRPI0712556A2 (pt) 2013-07-02
WO2007140154A2 (en) 2007-12-06
EP2029556A2 (en) 2009-03-04
CL2007001454A1 (es) 2008-05-16
EP2029556B1 (en) 2010-11-03
MA30482B1 (fr) 2009-06-01
PT2029556E (pt) 2011-01-31
US20090163478A1 (en) 2009-06-25
JP2009538330A (ja) 2009-11-05
ATE486858T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
BRPI0413849A (pt) metanossulfonato de etiléster de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamin o]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2 -il-amino]-propiÈnico e seu uso como medicamento
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
NO20076658L (no) Heteroarylbenzamidderivater for anvendelse som GLK aktivatorer ved behandling av diabetes
NO20073875L (no) Krystallformer av 1-klor-4-(B-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzyl]-benzen, metode for fremstilling samt anvendelse for fremstilling av medikamenter
NO20023786D0 (no) Heteroaromatiske karboksamidderivater og deres anvendelse som inhibitorer av enzymet IKK-2
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
MY155230A (en) Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine
SG140591A1 (en) Heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
HUP0301513A2 (hu) O-Aril-glükozid SGLT2 inhibitorok és eljárás elżállításukra
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
NO20082395L (no) Krystallinske former av 1'-(1-metyl)-4'-[(2-fluor-4-metoksyfenyl)metyl]-5'-metyl-1H-pyrazol-3'-O-beta-D-glucopyranosid, en fremstillingsmetode og anvendelse av denne for fremstilling av medikamenter
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents
NO20070089L (no) DPP-IV inhibitorer
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
BRPI0517033A (pt) novos derivados de hidantoìna como inibidores de metaloproteinase
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20083068L (no) Optisk aktive karbamater, fremgangsmate for deres fremstilling og anvendelse derav som farmasoytiske mellomprodukter
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
SE0400850D0 (sv) Novel Compounds
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
WO2007024600A3 (en) Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
BR0312593A (pt) Aciluréias substituìdas por uréia e uretano, processo para a sua produção e sua aplicação

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application